Insider Trading Alert - IPXL, OKE And OXY Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 21, 2014, 140 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $401.00 to $744,000,000.00.

Highlighted Stocks Traded by Insiders:

Impax Laboratories (IPXL) - FREE Research Report

Terreri Peter R, who is Director at Impax Laboratories, sold 666 shares at $26.07 on May 21, 2014. Following this transaction, the Director owned 44,520 shares meaning that the stake was reduced by 1.47% with the 666-share transaction.

The shares most recently traded at $27.29, up $1.22, or 4.47% since the insider transaction. Historical insider transactions for Impax Laboratories go as follows:

  • 4-Week # shares sold: 228,235
  • 12-Week # shares sold: 232,235
  • 24-Week # shares sold: 235,235

The average volume for Impax Laboratories has been 777,400 shares per day over the past 30 days. Impax Laboratories has a market cap of $1.9 billion and is part of the health care sector and drugs industry. Shares are up 5.37% year-to-date as of the close of trading on Wednesday.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products. The company operates through two segments, Global Pharmaceuticals Division and Impax Pharmaceutical Division. The company has a P/E ratio of 2666.0. Currently, there are 2 analysts who rate Impax Laboratories a buy, 2 analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPXL - FREE

TheStreet Quant Ratings rates Impax Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Impax Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ONEOK (OKE) - FREE Research Report

Christensen Wesley John, who is Sr Vp Operations at ONEOK, sold 11,693 shares at $62.27 on May 21, 2014. Following this transaction, the Sr Vp Operations owned 9,981 shares meaning that the stake was reduced by 53.95% with the 11,693-share transaction.

The shares most recently traded at $64.84, up $2.57, or 3.97% since the insider transaction. Historical insider transactions for ONEOK go as follows:

  • 12-Week # shares sold: 1,900
  • 24-Week # shares sold: 1,900

The average volume for ONEOK has been 1.1 million shares per day over the past 30 days. ONEOK has a market cap of $13.1 billion and is part of the utilities sector and utilities industry. Shares are up 2.46% year-to-date as of the close of trading on Wednesday.

ONEOK, Inc. operates as a diversified energy company in the United States. The stock currently has a dividend yield of 3.54%. The company has a P/E ratio of 43.9. Currently, there are 6 analysts who rate ONEOK a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OKE - FREE

TheStreet Quant Ratings rates ONEOK as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk, deteriorating net income and poor profit margins. Get the full ONEOK Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Occidental Petroleum (OXY) - FREE Research Report

Klesse William R, who is Director at Occidental Petroleum, bought 5,000 shares at $95.50 on May 21, 2014. Following this transaction, the Director owned 23,620 shares meaning that the stake was boosted by 26.85% with the 5,000-share transaction.

The shares most recently traded at $97.77, up $2.27, or 2.32% since the insider transaction. Historical insider transactions for Occidental Petroleum go as follows:

  • 4-Week # shares bought: 5,000
  • 12-Week # shares bought: 5,000
  • 24-Week # shares bought: 11,500
  • 24-Week # shares sold: 17,000

The average volume for Occidental Petroleum has been 3.8 million shares per day over the past 30 days. Occidental Petroleum has a market cap of $75.0 billion and is part of the basic materials sector and energy industry. Shares are up 2.62% year-to-date as of the close of trading on Wednesday.

Occidental Petroleum Corporation is engaged in the acquisition, exploration, and development of oil and gas properties in the United States and internationally. The company operates in three segments: Oil and Gas; Chemical; and Midstream, Marketing and Other. The stock currently has a dividend yield of 3.02%. The company has a P/E ratio of 12.9. Currently, there are 11 analysts who rate Occidental Petroleum a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OXY - FREE

TheStreet Quant Ratings rates Occidental Petroleum as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Occidental Petroleum Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers